RepliCel Life Sciences is developing an autologous cell-based procedure for the treatment of androgenetic alopecia (pattern baldness) and general hair loss in men and women. The procedure has the potential to become the first minimally invasive solution for hair loss.

(Part 1 of 4) Tobin Smith sits down with RepliCel Life Sciences ($REPCF.OB) CEO David Hall to explore the company's breakthrough procedure that aims to bypass traditional hair transplantation and instead create a non-invasive method of transplanting hair cells.

The outcome of this exciting technology is to both rejeuvenate existing hair follicles as well as to grow brand-new ones in a natural-looking way.

The market is definitely there for this alternative to today's gold standard, which is microtransplantation. Because many people either don't qualify for a hair transplant or they simply don't want to go the transplant route, RepliCel's breakthrough technology makes sense for both potential patients AND investors. Learn why in this video...

(Part 4 of 4) Tobin Smith and RepliCel Life Sciences ($REPCF.OB) CEO David Hall examine the "regenerative arts" marketplace for hair loss solutions, where more than 60% of women and men would prefer to have more hair than anything else (i.e., friends, money). 

In this video clip, Mr. Hall shares details about the company's clinical trials, plans for the next phase of trials and the benchmarks to measure their success. The results have been encouraging to date, and we expect a lot more good news to come from the trials and, ultimately, the shares.